Title : Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.

Pub. Date : 2010 Jan

PMID : 19794412






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
2 Sulfonylureas are metabolized mainly by the cytochrome p450 2C9 (CYP2C9) enzyme. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
3 Sulfonylureas are metabolized mainly by the cytochrome p450 2C9 (CYP2C9) enzyme. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
4 In conclusion, CYP2C9 loss-of-function alleles are associated with greater response to sulfonylureas and decreased failure of therapy consistent with the pharmacokinetic role of CYP2C9. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens